Key facts
- It has raised $5.5M; the latest was Early Stage VC ($5.5M) in Nov 2025.
- Notable investors include Fifty Years, Age 1, Moth Fund.
- Status: Privately Held (backing).
Investors
3- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for General Control
- ·The full record, as it builds
Funding rounds
No funding rounds for General Control are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About General Control
Developer of multiplexed epigenetic medicines designed to address the complexity of age-related diseases. The company's platform enables coordinated, reversible control of multiple gene expressions within a single therapy by utilizing programmable epigenetic editing technologies, allowing researchers and clinicians to target interconnected disease pathways and phenotypes.
- Sector
- Healthcare
- HQ
- San Francisco, CA, United States
- Founded
- 2024
- Employees
- 3
- Website
- generalcontrol.inc/
- Ownership
- Privately Held (backing)
General Control doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in General Control shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on General Control in its N-PORT filings yet. We sweep new filings monthly.